An endocrinologist warns psychiatrists against overreading peripheral thyroid hormones and flags kelp and T3 microdosing as underrecognized risks.
|Videos|October 8, 2020
World CME Conference™ Preview: The Interplay of Migraines and Psychiatric Disorders
Author(s)Heidi Moawad, MD
Enjoy this preview of Dr Moawad's talk for the upcoming CME Conference.
Advertisement
Dr Moawad is Associate Editor Humanities in Neurology, Clinical Assistant Professor Case Western Reserve University School of Medicine, Div. of Medical Education, and Editor in Chief Emeritus of Neurology Times (2017-2019).
Interested in hearing more? Join us at the
Advertisement
Related to this article
Phase 2 trial finds bezisterim shows safety and symptom gains in long COVID, with strongest benefits for severe fatigue, PEM, and cognitive issues.
Adjustment disorder often goes undiagnosed after major life stressors, especially in cancer care; learn updated criteria, risks, and emerging therapies like psilocybin.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Antipsychotic levels clarify adherence, guide dose escalation up to a point of futility, and offer more than pharmacogenetic testing, says Jonathan Meyer, MD.
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.
Advertisement
Advertisement
Trending on Psychiatric Times
1
New Phase 2 Data on Bezisterim for the Treatment of Long COVID
2
Dosing MDD Therapies in Medically Complex Patients: Metabolism and Interactions
3
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
4
Choosing an Antidepressant: Art, Science, and Knowing Your Patient
5